drugset / Trial / NCT00077844

Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)

NCT00077844

Phase 2/3 Completed 3532 enrolled Sanofi
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of non-coronary artery bypass graft (CABG) major and minor bleeding.

Timeline

Start
2004-01
Primary completion
2005-09
Completion
2005-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Enoxaparin sodium Other / unclassified 0.5 mg/kg Intravenous
Subject Enoxaparin sodium Other / unclassified 0.75 mg/kg Intravenous

Indications

No indication recorded.